Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $101 | $68 | $45 | $291 |
| Short-Term Investments | $319 | $284 | $144 | $0 |
| Receivables | $4 | $6 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $16 | $12 | $21 | $8 |
| Total Curr. Assets | $440 | $370 | $210 | $299 |
| Property Plant & Equip (Net) | $82 | $93 | $33 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $7 | $9 | $1 |
| Total NC Assets | $86 | $99 | $42 | $7 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $526 | $469 | $252 | $306 |
| Liabilities | – | – | – | – |
| Payables | $4 | $3 | $6 | $1 |
| Short-Term Debt | $8 | $8 | $8 | $0 |
| Tax Payable | $1 | $4 | $0 | $0 |
| Deferred Revenue | $14 | $132 | $0 | $0 |
| Other Curr. Liab. | $13 | $11 | $8 | $6 |
| Total Curr. Liab. | $39 | $159 | $22 | $7 |
| LT Debt | $52 | $60 | $18 | $0 |
| Deferred Rev, NC | $7 | $8 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $58 | $68 | $18 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $59 | $68 | $26 | $0 |
| Total Liabilities | $98 | $227 | $40 | $7 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$129 | -$195 | -$188 | -$94 |
| AOCI | -$0 | $0 | -$2 | $0 |
| Other Equity | $558 | $437 | $403 | $392 |
| Total Equity | $429 | $242 | $213 | $299 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $526 | $469 | $252 | $306 |
| Net Debt | -$42 | $1 | -$19 | -$291 |